842-1 Anemia in diastolic heart failure is frequent and associated with worse outcome  by Brucks, Steffen et al.
216A ABSTRACTS - Cardiac Function and Heart Failure JACC March 3, 2004
Ca
rd
ia
c 
Fu
nc
tio
n 
an
d 
He
ar
t F
ai
lu
re
1.4, respectively, p=0.003). HW/BW, LV wall thickness and myocyte disarray were
unchanged with therapy. Levels of oxidized nuclear but not mitochondrial DNA was
increased in the cTnT-Q92 mice and reduced to normal in the NAC group. Similarly,
expression levels of signaling kinases p-ERK1/2 were increased in the cTnT-Q92 and
normalized with NAC. Thus, treatment with anti-oxidant NAC reduces myocardial oxida-
tive stress and normalizes IF in a mouse model of hypertrophic cardiomyopathy. The
results in a genetic animal model of HCM, show the potential salutary effects of NAC in
reversal of interstitial fibrosis, implicated in arrhythmogenesis, in HCM, which is the most
common cause of sudden cardiac death in the young and a major cause of mortality and
morbidity in elderly.
11:30 a.m.
839-5 Two Transgenic Animal Models Expressing Human 
Troponin T Gene Mutations: One Exhibiting Dilated 
Cardiomyopathy (W141) and the Other Exhibiting 
Hypertrophic Cardiomyopathy (Q92)
Jasvinder Sidhu, Duanxiang Li, Zhinong Wang, A.J. Marian, Francesco J. DeMayo, 
George E. Taffet, Robert Roberts, Baylor College of Medicine, Houston, TX
Background: The usual response of the heart is hypertrophy. Decompensation and sub-
sequent heart failure often occurs after transition from hypertrophy to dilatation but
appears to reflect an inhibition of growth. Troponin T (cTnT) mutations have been identi-
fied to cause familial hypertrophic cardiomyopathy (HCM) and others familial dilated car-
diomyopathy (DCM). Thus, different mutations of the same gene induce different growth
patterns. HCM is induced by cTnT Q92 and DCM by cTnT W141 mutations.
Methods: We generated a transgenic mouse (TM) expressing the cTnT Q92 mutation
with a phenotype of HCM and a TM expressing the cTnT W141 with a phenotype of DCM
using alpha MHC as the cardiac specific promotor.
Results: The HCM phenotype (cTnT Q92) has normal heart size with sarcomere disarray,
fibrosis and an increased cardiac ejection rate 73.9 ± 9.4. In contrast, the DCM pheno-
type cTnT W141 has a large dilated heart without fibrosis but with decreased contractility.
Echo analysis was normal at 4 weeks but at 12 weeks showed: Diastolic left ventricular
dimension (LVD) in non-transgene (NT) was 3.68 + .06 versus 4.77 + .20 (p< .05) in TM;
systolic LVD of 2.32 + .09 in NT versus 4.01 + .20 in TM; fractional shortening rate of NT
was 0.37 + .01 versus 0.16 + .009 in TM; and peak ejection rate of 113 + 5 in NT versus
84 + 4 in TM. Gene microarray and northern analysis of myocardial gene expression in
HCM and DCM were performed for markers associated with a hypertrophic growth
response: Expression of IGF and ANP was normal in HCM and DCM. In contrast, skele-
tal alpha actin was decreased in HCM but increased in DCM. BNP normal in HCM was
increased in DCM. GP130, increased in HCM was decreased 1 to 2 fold in DCM. Conclu-
sion: GP130 a cytokine receptor claimed to be necessary for the hypertrophic growth
response was down regulated in our DCM model and thus, may play a pivotal role in the
lack of a hypertrophic growth response. Differential analysis of the GP130 pathway in the
two models should determine whether this pathway is responsible for lack of the growth
response in DCM.
11:45 a.m.
839-6 Role of Left Atrial Contractile Function in Functional 
Capacity of Patients With Hypertrophic Nonobstructive 
Cardiomyopathy
Yukitaka Shizukuda, Vandana Sachdev, Cynthia L. Brenneman, Charles W. Birdsall, 
Lameh Fananapazir, Jonathan F. Plehn, National Heart, Lung, and Blood Institute, 
Bethesda, MD
Background: Left atrial (LA) dilatation and reduced atrial contractile function have been
demonstrated in symptomatic patients with hypertrophic, non-obstructive cardiomyopa-
thy (HNCM), suggesting the presence of a primary atrial myopathy. Since LA contractile
function partially governs left ventricular (LV) preload reserve and maintenance of the
Frank-Starling mechanism, LA systolic dysfunction could provide a mechanism for exer-
cise intolerance in HNCM. We, therefore, evaluated LA contractile function in 50 patients
with HNCM (mean age=37+10 years, 29 men/21 women) with normal LVEF
(mean=69±6%) who were stratified for symptoms of congestive heart failure. Methods:
We analyzed LA volume normalized to body surface area, active atrial ejection fraction
(LAEF), ejection force (LAF), and kinetic energy (LAKE), in asymptomatic (Group 1,
n=19) and symptomatic (Group 2, n=31) subjects and compared these parameters to
symptom-limited metabolic stress testing performed within one week of echocardio-
graphic examination. Results: MRI-derived LV mass was similar between Groups 1 and 2
(mean=229 +68 vs. 223 + 78 gms, respectively, p=NS) and there were no differences in
LAEF, LAF or LAKE in symptomatic versus asymptomatic subjects [59.8 +19.9% vs.
60.6+22.8%, 14.7+8.7 vs. 15.6+11.2 (kdyne), 16.6+19.7 vs. 10.4+13.0 (kerg), respec-
tively]. While resting LAEF correlated weakly with exercise time (r=0.319, p<0.05), it did
not predict MVO2 or anaerobic threshold (p=NS for both). Neither were LAF nor LAKE
associated with any objective exercise parameter. Maximum LA volume, an index of LA
volumetric remodeling, was inversely correlated with peak MVO2 (r=-0.32, p<0.05). Con-
clusion: These data suggest that resting atrial contractile function is not a determinant of
functional capcity in patients with HNCM. Possibly, atrial contractile reserve associated
with exercise might be a more important factor for limitation of functional capacity in these
patients.
ORAL CONTRIBUTIONS
842 Heart Failure and Anemia
Tuesday, March 09, 2004, 10:30 a.m.-Noon
Morial Convention Center, Room 257
10:30 a.m.
842-1 Anemia in Diastolic Heart Failure Is Frequent and 
Associated With Worse Outcome
Steffen Brucks, William C. Little, Tania Chao, Ronald L. Rideman, Bharathi Upadhya, 
Deborah Wesley-Farrington, David C. Sane, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background: Many patients with heart failure (HF) and a reduced ejection fraction (EF)
have anemia. The prevalence and importance of anemia in patients with HF and a nor-
mal EF (diastolic HF) are not known. Thus, we hypothesize that anemia is common in
diastolic HF and associated with a worse outcome.
Methods: We evaluated 137 patients with clinical evidence of HF and a normal EF (>
0.50).
Results: The age was 65±15 (mean ± SD) years, and 58% were women. Anemia (hemo-
globin, Hb, < 12 gm/dl in women; < 13 gm/dl in men) was common, occurring in 45% of
patients. Patients with and without anemia had similar ages (65±15 vs 65±14), EF
(0.62±0.08 vs 0.61±0.07), LV mass (213±77 vs 193±85 gms), and systolic mitral annular
velocity (6.8±1.5 vs 6.9±2.1 cm/sec). Patients with anemia had a higher brain natriuretic
peptide (BNP) (322±330 vs 160±240 pg/ml, p<0.001), worse diastolic dysfunction grade
by mitral Doppler (1.3±8 vs 0.8±7, p<0.001), and a higher ratio of peak mitral inflow
velocity to mitral annular velocity (E/EM) (13.5±6.5 vs 9.7±4.2, p<0.001) compared to
patients without anemia. Reduced Hb concentration correlated with both elevated BNP
(r2=0.15, p<0.0001) and E/EM (r2=0.15, p<0.0001). Patients with anemia had a reduced
two-year cardiac hospitalization-free survival (hazard ratio 2.0, p<0.05)
Conclusion: Anemia is common in pts with HF and a normal EF (diastolic HF) and is
associated with greater elevations in BNP, more severe diastolic dysfunction, and a
worse prognosis.
10:45 a.m.
842-2 Hemoglobin Level Is Associated With Mortality and 
Hospitalization in Patients With Severe Chronic Heart 
Failure: Results From the COPERNICUS Study
Stefan D. Anker, Andrew JS Coats, Ellen B. Roecker, Paul Mohacsi, Jean Rouleau, 
Henry Krum, Armin Scherhag, Milton Packer, for the COPERNICUS study group, 
National Heart and Lung Institute, London, United Kingdom, Applied Cachexia Research, 
Charite, Berlin, Germany
Background: Anemia has been shown to be a risk factor for mortality in mild to moder-
ate chronic heart failure (CHF), but its importance in severe CHF and its ability to predict
hospitalization has not been defined.
Methods: We evaluated the relationship between hemoglobin level and mortality and
hospitalization in 2286 patients (1822 men, 464 women) with severe CHF enrolled in the
COPERNICUS study. All enrolled patients had dyspnea or fatigue at rest or on minimal
exertion for at least 2 months and a left ventricular ejection fraction <25%.
Results: There was a highly significant (P<0.0001) but small (r = -0.089) inverse relation-
ship between baseline hemoglobin and creatinine levels. Patients with low hemoglobin
were at significantly higher risk of a major clinical events, the magnitude of risk decreas-
ing with increasing hemoglobin, both in univariate analyses (all P<0.001) and in multivari-
ate analyses which adjusted for sex and other predictors of risk, including age, left
ventricular ejection fraction, creatinine, body mass index, systolic blood pressure, CHF
etiology and treatment with carvedilol (all P<0.01). Mean creatinine levels and one-year
Kaplan-Meier event rates are shown below: 
Conclusion: Low hemoglobin is an independent risk factor for adverse outcomes in
patients with severe HF. Whether correction of anemia improves outcomes in CHF war-
rants further study.
Table
Hemoglob
in(g/dL)
N Creatinine 
(µmol/L)
All-Cause 
Mortality (%)
Death or HF 
Hospitalization 
(%)
Death or Any 
Hospitalization 
(%)
<11.0 115 151.5 23.2 46.6 64.1
11.0 - 
<12.5
315 135.8 16.7 36.1 51.0
12.5 - 
<13.5
432 133.2 13.5 30.5 48.3
13.5 - 
<15.0
834 132.7 15.6 31.9 45.5
15.0 - 16.5 463 131.2 13.1 26.5 42.9
>16.5 127 131.5 9.0 25.5 38.0
